Results 181 to 190 of about 27,004 (255)

Quality and reliability of myelodysplastic syndromes-related health information on Chinese short-video platforms: a multi-platform cross-sectional analysis. [PDF]

Front Digit Health
Yang R, Chen W, Xu C, Yan H, Dai W, Lin Y, Zhai Z, Zhang W, Tao Q.   +8 more
europepmc   +1 more source

Reversible Eltrombopag‐Associated Bone Marrow Fibrosis With Hematologic Recovery After Drug Withdrawal in ASXL1‐Mutated Hypoplastic Myelodysplastic Syndrome: A Case Report

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Hypoplastic myelodysplastic syndrome (MDS) often overlaps clinically with aplastic anemia and frequently involves clonal hematopoiesis. Thrombopoietin receptor agonists (TPO‐RAs), including eltrombopag, are increasingly used to treat cytopenias in hypoplastic marrow failure syndromes; however, their long‐term effects on clonal dynamics and ...
Kyoko Yoshihara, Ikuo Matsuda, Yasuhito Nannya, Mami Samori, Naru Tomigaki, Saki Takahashi, Chisato Ohe, Satoshi Yoshihara   +7 more
wiley   +1 more source

The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time-driven activity-based costing study. [PDF]

Br J Haematol
Mo A, Haysom H, Carrandi A, de Albornoz SC, Guglielmino J, Rushford K, Ellison A, Andrew D, Jesurajah A, Hu E, Banahene P, Hoo LS, Higgins AM, Shortt J, Wood EM, McQuilten ZK.   +15 more
europepmc   +1 more source

Cytomegalovirus in Bronchoalveolar Lavage Fluid: A Predictor of Outcome in Immunocompromised Patients

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Cytomegalovirus (CMV) is a prevalent herpesvirus that remains typically asymptomatic in immunocompetent individuals but can cause severe, potentially life‐threatening disease in immunocompromised patients. This study assessed the impact of CMV‐associated lower respiratory tract infections (LRTIs), diagnosed by polymerase chain reaction (PCR ...
Theodora Zouvani, Meropi Karakioulaki, Kathleen Jahn, Sebastian Fähndrich, Björn C. Frye, Leticia Grize, Eleni Papakonstantinou, Hartmut Hengel, Karoline Leuzinger, Hans H. Hirsch, Daiana Stolz   +10 more
wiley   +1 more source

Pre-transplant molecular international prognostic scoring system score reduction is not associated with improved outcomes in myelodysplastic syndromes. [PDF]

Blood Cancer J
Sakashita M, Kanda J, Hattori K, Hiramoto N, Kanemura N, Kasahara S, Watanabe M, Yoshihara S, Ichii M, Sezaki N, Tsuji M, Maeda T, Sasaki K, Kitano T, Miyahara Y, Kondo T, Sakata-Yanagimoto M, Takaori-Kondo A, Ogawa S, Nannya Y.   +19 more
europepmc   +1 more source

Impact of Co‐Morbid Immunocompromise in HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

The Laryngoscope, Volume 136, Issue 10, Page 4279-4289, October 2026.
Among patients with surgically resected Human Papillomavirus positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), immunocompromised patients had significantly worse overall survival compared to the non‐compromised group; however, these exploratory findings should be interpreted cautiously.
Maxwell L. Weng, Tereza Vitkovska, Song Hon Hwang, Lauran K. Evans, Hong‐Ho Yang, Christopher Dann, Dipti Sajed, Maie A. St. John   +7 more
wiley   +1 more source

Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review. [PDF]

Ann Hematol
Niscola P, Gianfelici V, Giovannini M, Mazzone C, Del Principe MI.   +4 more
europepmc   +1 more source

Glutamine Metabolism in Health and Diseases

MedComm, Volume 7, Issue 10, October 2026.
Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding, Fan Tong, Jing Zeng, Chun‐Ping Cui   +3 more
wiley   +1 more source

Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes. [PDF]

Blood Cancer J
Bazinet A, Bataller A, Chien K, Sasaki K, Montalban-Bravo G, Hammond D, Bouligny I, Swaminathan M, Jen WY, Kugler E, Kanagal-Shamanna R, Kadia T, Borthakur G, DiNardo C, Short N, Pemmaraju N, Jabbour E, Daver N, Ravandi F, Urrutia S, Gener-Ricos G, Braish J, Briski R, Rodriguez-Sevilla JJ, Li Z, Champlin RE, Shpall EJ, Alousi A, Oran B, Hosing C, Ramdial JL, Olson A, Pierce S, Chen J, Kantarjian H, Garcia-Manero G, Popat U.   +36 more
europepmc   +1 more source

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), Volume 73, Issue 7, Page 1141-1158, October 2026.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source